These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A novel liver zonation phenotype-associated molecular classification of hepatocellular carcinoma. Zhang T; Gu J; Wang X; Lu Y; Cai K; Li H; Nie Y; Chen X; Wang J Front Immunol; 2023; 14():1140201. PubMed ID: 36936935 [TBL] [Abstract][Full Text] [Related]
5. Advances in molecular classification and precision oncology in hepatocellular carcinoma. Rebouissou S; Nault JC J Hepatol; 2020 Feb; 72(2):215-229. PubMed ID: 31954487 [TBL] [Abstract][Full Text] [Related]
6. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation. Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529 [TBL] [Abstract][Full Text] [Related]
7. β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study. Ando S; Shibahara J; Hayashi A; Fukayama M Virchows Arch; 2015 Nov; 467(5):535-42. PubMed ID: 26311355 [TBL] [Abstract][Full Text] [Related]
8. Tumor heterogeneity in small hepatocellular carcinoma: analysis of tumor cell proliferation, expression and mutation of p53 AND beta-catenin. An FQ; Matsuda M; Fujii H; Tang RF; Amemiya H; Dai YM; Matsumoto Y Int J Cancer; 2001 Aug; 93(4):468-74. PubMed ID: 11477549 [TBL] [Abstract][Full Text] [Related]
9. Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification. Torbenson M; McCabe CE; O'Brien DR; Yin J; Bainter T; Tran NH; Yasir S; Chen ZE; Dhanasekaran R; Ahn KS; Roberts LR; Wang C Hum Pathol; 2022 Jan; 119():15-27. PubMed ID: 34592239 [TBL] [Abstract][Full Text] [Related]
10. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Boyault S; Rickman DS; de Reyniès A; Balabaud C; Rebouissou S; Jeannot E; Hérault A; Saric J; Belghiti J; Franco D; Bioulac-Sage P; Laurent-Puig P; Zucman-Rossi J Hepatology; 2007 Jan; 45(1):42-52. PubMed ID: 17187432 [TBL] [Abstract][Full Text] [Related]
11. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC. Charawi S; Just PA; Savall M; Abitbol S; Traore M; Metzger N; Ravinger R; Cavard C; Terris B; Perret C J Pathol; 2019 Apr; 247(4):435-443. PubMed ID: 30566242 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Tan PS; Nakagawa S; Goossens N; Venkatesh A; Huang T; Ward SC; Sun X; Song WM; Koh A; Canasto-Chibuque C; Deshmukh M; Nair V; Mahajan M; Zhang B; Fiel MI; Kobayashi M; Kumada H; Hoshida Y Liver Int; 2016 Jan; 36(1):108-18. PubMed ID: 26058462 [TBL] [Abstract][Full Text] [Related]
14. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma. Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368 [TBL] [Abstract][Full Text] [Related]
15. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Désert R; Rohart F; Canal F; Sicard M; Desille M; Renaud S; Turlin B; Bellaud P; Perret C; Clément B; Lê Cao KA; Musso O Hepatology; 2017 Nov; 66(5):1502-1518. PubMed ID: 28498607 [TBL] [Abstract][Full Text] [Related]
16. Computational analysis of TP53 vs. CTNNB1 mutations in hepatocellular carcinoma suggests distinct cancer subtypes with differential gene expression profiles and chromatin states. Biterge Süt B Comput Biol Chem; 2020 Dec; 89():107404. PubMed ID: 33096424 [TBL] [Abstract][Full Text] [Related]